Suppr超能文献

在药物评估期间识别有QT间期延长风险的患者:一个被错过的机会?

Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?

作者信息

Buss Vera H, Lee Kayla, Naunton Mark, Peterson Gregory M, Kosari Sam

机构信息

Faculty of Health, University of Canberra, Bruce, ACT 2617, Australia.

School of Medicine, University of Tasmania, Sandy Bay, TAS 7005, Australia.

出版信息

J Clin Med. 2018 Dec 10;7(12):533. doi: 10.3390/jcm7120533.

Abstract

The prolongation of the QT interval is a relatively rare but serious adverse drug reaction. It can lead to torsade de pointes, which is potentially life-threatening. The study's objectives were: determine the use of QT interval-prolonging drugs in an elderly community-dwelling population at risk of medication misadventure and identify recommendations regarding the risk of QT interval prolongation made by pharmacists when performing medication reviews. In a retrospective evaluation, 500 medication review reports from Australian pharmacists were analysed. In patients taking at least one QT interval-prolonging drug, the individual risk of drug-induced QT interval prolongation was assessed. Recommendations of pharmacists to avoid the occurrence of this drug-related problem were examined. There was a high prevalence of use of potentially QT interval-prolonging drugs (71% patients), with 11% of patients taking at least one drug with a known risk. Pharmacists provided specific recommendations in only eight out of 35 patients (23%) with a high-risk score and taking drugs with known risk of QT interval prolongation. Pharmacists' recommendations, when present, were focused on drugs with known risk of QT interval prolongation, rather than patients' additional risk factors. There is a need to improve knowledge and awareness of this topic among pharmacists performing medication reviews.

摘要

QT间期延长是一种相对罕见但严重的药物不良反应。它可导致尖端扭转型室性心动过速,这可能危及生命。该研究的目的是:确定在有用药差错风险的老年社区居住人群中QT间期延长药物的使用情况,并确定药剂师在进行药物审查时就QT间期延长风险提出的建议。在一项回顾性评估中,分析了来自澳大利亚药剂师的500份药物审查报告。在服用至少一种QT间期延长药物的患者中,评估了药物引起的QT间期延长的个体风险。审查了药剂师为避免出现这种药物相关问题而提出的建议。潜在的QT间期延长药物的使用率很高(71%的患者),11%的患者服用至少一种有已知风险的药物。在35名高危评分且服用有已知QT间期延长风险药物的患者中,只有8名(23%)患者得到了药剂师的具体建议。药剂师的建议(如有)主要集中在有已知QT间期延长风险的药物上,而不是患者的其他风险因素。有必要提高进行药物审查的药剂师对该主题的知识和认识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/774d/6306817/a5e3e807cfe0/jcm-07-00533-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验